 My name is Suzanne Lynch. I'm a professor at Columbia University in New York. Right now we have clinical trials with those monoclonal antibodies in newly diagnosed patients, in randomized trials, but also in relapsed refractory patients. And we think that probably in the future when you start to treat a patient with amyloidosis you will start to treat the patient with chemotherapy to target the plasma cells. But at the same time you give the patient a monoclonal antibody that is targeting the amyloid. So by this you have a dual approach. You eradicate the underlying disease, the abnormal plasma cell clone, but you also help the body to break down the amyloid recovery organ function. I think that is really important in amyloidosis and that's one of the big differences in contrast to multiple myeloma where we only focus on the underlying plasma cell dyscrasia. We have new and updated response criteria in amyloidosis. So in contrast to multiple myeloma and amyloidosis we focus very much on the free light chains. So I mentioned that the response criteria define a VGPR, a very good partial remission, if the difference between the involved and the uninvolved free light chains is less than four. So that's completely different how we assess response in multiple myeloma. I also documented or told the audience that the complete remission has to be maintained. Only when you maintain a complete remission the patients are able to have a long-term remission. We have many new treatments for multiple myeloma. So we have currently more options for amyloidosis that includes more proteasome inhibitors. We are using the new oroproteasome inhibitor exasome that was recently approved for multiple myeloma, more amyloidosis. We also use kafilzumib in selected cases and amyloidosis. I think what will be interesting to use deratutumib or ilotuzumib, those are monoclonal antibodies that destroy plasma cells to see what is their efficacy in multiple myeloma. There are some case reports and also my personal experience is that those antibodies, DERA and ilotuzumib can be quite effective in amyloidosis. But again, clinical trials are ongoing and I think in a couple of years we might know what's the role of those antibodies targeting plasma cells in amyloidosis.